ClotCare: Blood Clots, Stroke, Heart Attack
Thursday, November 21, 2024
Home   |   DVT/PE   |   Blood Clots   |   Coumadin/Warfarin   |   New Patients   |   Self Testing   |   Email List   |   Donate

Pick a Topic:

Find info on a:

We subscribe to the HONcode principles of the HON Foundation. Click to verify.
ClotCare complies with the HONcode standard for trustworthy health
information:
verify here.

ClotCare is a member of the Coalition to Prevent Deep Vein Thrombosis (DVT Coalition)  ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.

New Data on Treatment Duration for Provoked DVT

William E. Dager, Pharm.D., FCSHP
April 2004

Review: Kearon C, Ginsberg JS, Anderson DR, et al for the SOFAST Investigators. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost 2004;2:743-9.

The recent PREVENT and ELATE trials addressed the question of duration of anticoagulation therapy in patients with idiopathic venous thrombotic events (VTE). But what about the duration of anticoagulation therapy in patients with VTE associated with a predisposing acute event? This small study attempted to explore whether any differences in symptomatic VTE or bleeding occurred when treating a VTE with warfarin for either 1 month, or 3 months. Patients with known hypercoagulable states were excluded. The yearly rate of symptomatic VTE was higher in the 84 patients receiving 1 month of therapy (6.8%/yr) versus 81 receiving 3 months (3.2%/yr). No major bleeding was observed in either group. Of note is that additional events separating the two groups did not occur until 5 months post initiation of therapy, and that the observed VTE rates were higher then initially expected. The authors concluded that duration of anticoagulation therapy for VTE provoked by a transient risk factor should not be reduced from 3 months to 1 month.

The abstract of this article is available on PubMed, a service of the National Library of Medicine. Click here to access the abstract on PubMed.

Ask a question about blood clots or anticoagulant medications Have questions? Ask ClotCare. Send questions by email to webmaster@clotcare.org.

ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters.

Blood Clot Activities Calendar

New Postings:

Click here to view full list of new postings
ClotCare Home | New Postings | Patient Postings | Clinician Postings | Join Our Email List | Useful Web Links
CE Opportunities | Training Programs | DVT & PE Stories | Editorial Board | Financial Support
About ClotCare | DVT Coalition | Donate to ClotCare | Contact Us
Key topics discussed on ClotCare include: Blood Clots | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Atrial Fibrillation (A. Fib or AF) | Heart Attack | Stroke | Transient Ischemic Attack (TIA) | Mini Stroke | Bleeding Complications | Vascular Surgery | Surgical Blood Clot Removal | Warfarin | Coumadin | Lovenox | Low Molecular Weight Heparin (LMWH) | Heparin | Anticoagulants | Plavix | Aspirin | Antiplatelets | Blood Thinners
Copyright 2000-2018 by ClotCare. All rights reserved.
Terms, Conditions, & Privacy | Image Copyright Information
19260 Stone Oak Parkway, Suite 101 | San Antonio, TX 78258 | 210-860-0487
Send comments to webmaster@clotcare.org.
Thursday, November 21, 2024